The short version of Dihexa fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-19 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
== Toxicities == Nitrofurazone is suspected to be a human carcinogen and is included in California's list of toxic chemicals as defined by Proposition 65. Studies demonstrate that nitrofurazone induces mammary tumors (fibroadenoma and adenocarcinoma) in rats and ovarian tumors in mice. In addition, animal studies demonstrated an increased incidence in convulsive seizures, ovarian atrophy, testicular degeneration, and degeneration of articular cartilage. Proper personal protective equipment should be utilized when handling nitrofurazone.
As of late 2007, two structures have been solved for this class of enzymes, with PDB accession codes PDB: 1Q7L and PDB: 1YSJ. These structures also correspond to two known primary amino acid sequences for aminoacylases. The associated papers identify two types of domains comprising aminoacylases: Zinc binding domains - which bind Zn2+ ions - and domains that facilitate dimerization of Zinc binding domains. It is this dimerization that allows catalysis to occur, since aminoacylase's active site lies between its two Zinc binding domains. Bound Zinc facilitates the binding of the N-acyl-L-amino acid substrate, causing a conformational shift that brings the protein's subunits together around the substrate and allowing catalysis to occur. Aminoacylase 1 exists in a heterotetrameric structure, meaning 2 Zinc binding domains and 2 dimerization domains come together to make aminoacylase 1's quaternary structure.
=== Moondust: Knuckles Tech Demos === Moondust: Knuckles Tech Demos is a tech demo created for the Valve Index controllers which is set in the Portal universe. The game was released on Steam on June 21, 2018, however it is unlisted.
=== America, Iran, and Under Milk Wood, 1950–1953 === American poet John Brinnin invited Thomas to New York, where in February 1950 they embarked on a lucrative three-month tour of arts centres and campuses. The tour, which began in front of an audience of a thousand at the Kaufmann Auditorium of the Poetry Centre in New York, took in about 40 venues. During the tour, Thomas was invited to many parties and functions and on several occasions became drunk—going out of his way to shock people—and was a difficult guest. Thomas drank before some of his readings, though it is argued he may have pretended to be more affected by it than he actually was. The writer Elizabeth Hardwick recalled how intoxicating a performer he was and how the tension would build before a performance: "Would he arrive only to break down on the stage? Would some dismaying scene take place at the faculty party? Would he be offensive, violent, obscene?" Caitlin said in her memoir, "Nobody ever needed encouragement less, and he was drowned in it." On returning to Britain, Thomas began work on two further poems, "In the white giant's thigh", which he read on the Third Programme in September 1950, and the incomplete "In country heaven". In October, Thomas sent a draft of the first 39 pages of 'The Town That Was Mad' to the BBC. The task of seeing this work through to production as Under Milk Wood was assigned to the BBC's Douglas Cleverdon, who had been responsible for casting Thomas in 'Paradise Lost'.
Sources: en.wikipedia.org
=== Nile red === Nile red (also known as Nile blue oxazone) is formed by boiling Nile blue with sulfuric acid. This produces a mix of Nile red and Nile blue. Nile red is a lipophilic stain; it will accumulate in lipid globules inside cells, staining them red. Nile red can be used with living cells. It fluoresces strongly when partitioned into lipids, but practically not at all in aqueous solution.
=== Other symptoms and comorbidities === Myoglobinuria (reddish-brown urine) may be seen due to the breakdown of skeletal muscle known as rhabdomyolysis (a condition in which muscle cells breakdown, sending their contents into the bloodstream). In 2020, the largest study to-date of 269 GSD-V patients, 39.4% reported no previous episodes of myoglobinuria and 6.8% had normal CK (including those with fixed muscle weakness); so an absence of myoglobinuria and normal CK should not rule out the possibility of the disease. Between 33-51.4% develop fixed muscle weakness, typically of the trunk and upper body, with the onset of muscle weakness usually occurring later in life (40+ years of age). Younger people may display unusual symptoms, such as difficulty chewing, swallowing, or utilizing normal oral motor functions. Idiopathic leg pains were common in children, usually occurring at night, often presumed to be "growing pains" and not investigated further. Several comorbidities were found in GSD-V individuals at a higher rate than in the general population, including (but not limited to): hypertension (17%), endocrine diseases (15.7%), musculoskeletal/rheumatic disease (12.9%), hyperuricemia/gout (11.6%), gastrointestinal diseases (11.2%), neurological disease (10%), respiratory disease (9.5%), and coronary artery disease (8.3%). They may have a pseudoathletic appearance of muscle hypertrophy (24%), particularly of the legs, and may have lower bone mineral content and density in the legs.
Smoking has become less popular, but is still a large public health problem globally. Worldwide, smoking rates fell from 41% in 1980 to 31% in 2012, although the actual number of smokers increased because of population growth. In 2017, 5.4 trillion cigarettes were produced globally, and were smoked by almost 1 billion people. Smoking rates have leveled off or declined in most countries, but are increasing in some low- and middle-income countries. The significant reductions in smoking rates in the United States, United Kingdom, Australia, Brazil, and other countries that implemented strong tobacco control programs have been offset by increasing consumption in low income countries, especially China. The Chinese market now consumes more cigarettes than all other low- and middle-income countries combined. Other regions are increasingly playing larger roles in the growing global smoking epidemic. The WHO Eastern Mediterranean Region (EMRO) now has the highest growth rate in the cigarette market, with more than a one-third increase in cigarette consumption since 2000. Due to its recent dynamic economic development and continued population growth, Africa presents the greatest risk in terms of future growth in tobacco use. Within countries, patterns of cigarette consumption also can vary widely. For example, in many of the countries where few women smoke, smoking rates are often high in males (e.g., in Asia). By contrast, in most developed countries, female smoking rates are typically only a few percentage points below those of males.
Sources: en.wikipedia.org
According to a 2003 report by Human Rights Watch, an estimated 15 million children in debt bondage in India work in slavery-like conditions to pay off their family's debts. Slavoj Žižek asserts that new forms of contemporary slavery have been created in the post-Cold War era of global capitalism, including migrant workers deprived of basic civil rights on the Arabian Peninsula, the total control of workers in Asian sweatshops and the use of forced labor in the exploitation of natural resources in Central Africa.
== Ease of doing business == World Bank's Doing Business 2017; Equal Opportunity for All: Thailand ranked 46th (1-easiest; 190=difficult) of 190 nations in the "Ease of Doing Business" rankings. Other ASEAN states ranked: Singapore, 2; Malaysia, 23; Brunei, 72; Vietnam, 82; Indonesia, 91; Philippines, 99; Cambodia, 131; Laos, 139; Myanmar, 170. World Bank's Doing Business 2016: Measuring Regulatory Quality and Efficiency: Thailand ranked 49th overall of 189 nations (1=best, 189=worst) in ease of doing business, a drop of three places in the rankings since the 2014 survey prior to the May coup. Among ASEAN nations, Thailand ranked third behind Singapore and Malaysia. In detailed rankings, Thailand ranked 97th worldwide in getting credit, 96th in ease of starting a business, 70th in paying taxes, 39th in dealing with construction permits, 57th in registering property and enforcing contracts, 56th in trading across borders, 36th for protecting minority investors, and 49th in resolving insolvency.
=== Industrial uses === Some industrial processes, notably in the semiconductor and pharmaceutical industries, need large amounts of very pure water. In these situations, feedwater is first processed into purified water and then further processed to produce ultrapure water. Another class of ultrapure water used for pharmaceutical industries is called Water-For-Inject (WFI), typically generated by multiple distillation or compressed-vaporation process of DI water or RO-DI water. It has a tighter bacteria requirement as 10 CFU per 100 mL, instead of the 100 CFU per mL per USP.
Sigma-Aldrich Fine Chemicals (SAFC) is the fine chemical supply branch of Sigma-Aldrich specializing in raw materials for cell culture products; customized services for raw materials, manufacturing of active pharmaceutical ingredients. Sigma Life Science provides products such as custom DNA/RNA oligos; custom DNA and LNA probes; siRNA; isotopically-labelled peptides and peptide libraries. Sigma Advanced Genetic Engineering (SAGE) Labs was a division within Sigma-Aldrich that specializes in genetic manipulation of in vivo systems for special research and development applications. It was formed in 2008 to investigate zinc finger nuclease technology and its application for disease research models. Located in St. Louis, Missouri, SAGE Labs have developed knockout rats for the study of human diseases and disorders (such as autism), which are sold for up to US$95,000. SAGE also announced its first successful effort in creating a "knockout rabbit". Its facilities include a specific pathogen free, biosecure vivarium as well as research and development labs. SAGE Labs was acquired by Horizon Discovery Group in 2014. Carbolabs produces research quantities of chemicals produced by phosgenation reactions. The company was acquired in 1998. BioReliance provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production. The company was acquired by Sigma Aldrich in January 2012.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.